Quick Answer
TriSalus Life Sciences, Inc. reported Stockholders Equity of -$33.86 million for the year ending 2025.
- TriSalus Life Sciences, Inc. showed a decrease of -30.8% in Stockholders Equity from 2024 to 2025.
- This data is from TriSalus Life Sciences, Inc.'s annual report (Form 10-K), filed with the SEC on March 5, 2026.
- XBRL data for this metric is available from 2020 to 2025 (7 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2021: $5.00 million | Q2 2021: $5.00 million | Q3 2021: -$19.61 million | Q1 2022: -$137.35 million | Q2 2022: -$145.96 million | Q3 2022: -$153.93 million | Q1 2023: -$184.52 million | Q2 2023: -$198.42 million | Q3 2023: $8.29 million | Q1 2024: -$36.04 million | Q2 2024: -$25.26 million | Q3 2024: -$20.43 million | Q1 2025: -$34.37 million | Q2 2025: -$19.42 million | Q3 2025: -$26.73 million.
- Historical annual values: Fiscal year 2025: -$33.86 million | Fiscal year 2024: -$25.89 million | Fiscal year 2023: -$27.07 million | Fiscal year 2022: -$177.13 million | Fiscal year 2021: -$129.61 million | Fiscal year 2020: -$21.48 million | Fiscal year 2020: $0.00.
- Data sourced from SEC EDGAR public filings as of August 7, 2026.
Last verified: